ARTICLE | Product Development
CanSino vaccine first to gain approval as Gilead reveals remdesivir price
U.S. insurers will pay $3,120 per course for antiviral, CanSino COVID-19 vaccine approved for military personnel
June 30, 2020 1:35 AM UTC
Updated on Jun 30, 2020 at 4:54 PM UTC
CanSino received “military specially-needed drug approval” in China for its vaccine, making it the first vaccine to be authorized for use albeit in a limited population.
The announcement came as Gilead Sciences Inc. (NASDAQ:GILD) announced a price of $3,120 per treatment course of remdesivir for private insurers in the U.S., with the price for certain federal agencies and developed countries about $800 less...